Compare KKR & Co Inc (KKR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Revvity Inc — how do they compare? KKR & Co Inc trades at $90.95 (market cap $80.39B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: KKR & Co Inc is far larger — about 4.7× Revvity Inc's market cap, and KKR & Co Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Revvity Inc for 12 Days on average.
| KKR | RVTY | |
|---|---|---|
Market Cap | $80.39B | $16.98B |
Volume | 6,517,705 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $142.75 | $157.36 |
52-Week Low | $83.88 | $82.26 |
Typical Hold Time | 67 Days | 12 Days |
Enterprise Value | $2.95B | $19.30B |
Dividend Yield | 0.87% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $90.95, up 1.43% on the day, with strong analyst support showing 24 buy ratings and a $123.30 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Technical indicators are bearish overall, with RSI levels suggesting potential oversold conditions. The company maintains solid profitability with 14.97% net income margin and continues active portfolio management through recent acquisitions and divestitures.
The investment case for KKR appears favorable given the significant upside to analyst targets and strong institutional support. However, investors face risks from volatile cash flows, high debt levels, and market-sensitive revenue streams. The upcoming Q3 2026 earnings report on November 9 will be crucial for validating current valuation metrics.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
